卒中发作时预防性低分子肝素患者静脉溶栓的安全性与结局
该组症状性颅内出血和7天死亡调整比值比无显著增加,但3个月死亡和功能依赖风险升高,倾向评分匹配后仅3个月死亡差异仍存在。
要点
- 卒中发作时预防性低分子肝素不增加症状性颅内出血风险
- 该组7天死亡风险无显著增加,但3个月死亡风险升高
- 倾向评分匹配后仅3个月死亡差异仍存在
核心结论
- 急性缺血性卒中发作时使用预防性低分子肝素的患者静脉溶栓不增加症状性颅内出血或早期死亡风险。
主要发现
- 低分子肝素组患者更年长、卒中更严重、病前残疾和合并症更多。
- 症状性颅内出血调整比值比无显著增加:SITS-MOST标准aOR 1.02(95%CI 0.48-2.17),ECASS II标准aOR 0.95(95%CI 0.59-1.53)。
- 7天死亡aOR 1.14(95%CI 0.82-1.59),无显著增加。
- 3个月死亡aOR 1.94(95%CI 1.49-2.53),功能依赖aOR 1.44(95%CI 1.10-1.90),均升高。
- 倾向评分匹配后除3个月死亡外,其他结局组间差异消失。
临床怎么用
- 卒中发作时使用预防性低分子肝素的患者静脉溶栓不增加症状性颅内出血和早期死亡风险,可考虑溶栓。
- 需关注该类患者3个月死亡风险可能升高,加强远期随访。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background and Purpose- There are limited data on intravenous thrombolysis treatment in patients with ischemic stroke who have received prophylactic doses of low molecular weight heparins (LMWHs). We aimed to evaluate the safety and outcomes of intravenous thrombolysis treatment in stroke patients taking thromboprophylactic doses of LMWH. Methods- We analyzed 109 291patients treated with intravenous thrombolysis, recorded in the Safe Implementation of Treatments in Stroke International Thrombolysis Register between 2003 and 2017 not taking oral anticoagulants or therapeutic doses of heparin at stroke onset. One thousand four hundred eleven patients (1.3%) were on prophylactic LMWH for deep venous thrombosis prevention. Outcome measures were symptomatic intracerebral hemorrhage, parenchymal hematoma, death within 7 days and 3 months, and functional dependency at 3 months. Results- Patients on LMWH were older, had more severe strokes, more prestroke disability, and comorbidities than patients without LMWH. There was no significant increase in adjusted odds ratios (aOR) for symptomatic intracerebral hemorrhage (aOR, 1.02 [95% CI, 0.48-2.17] as per Safe Implementation of Treatments in Stroke -MOST, aOR, 0.95 [0.59-1.53] per ECASS II]), nor for 7-day mortality (aOR, 1.14 [0.82-1.59]), in the prophylactic LMWH group. The LMWH group had a higher aOR for 3-month mortality (aOR, 1.94 [1.49-2.53]) and functional dependency, aOR, 1.44 (1.10-1.90). Propensity score analysis matching patients on baseline characteristics removed differences between groups on all outcomes except 3-month mortality. Conclusions- Intravenous thrombolysis in patients with acute ischemic stroke on treatment with prophylactic doses of LMWH at stroke onset is not associated with an increased risk of symptomatic intracerebral hemorrhage or early death.
引用
- Cooray C, Mazya M, Mikulik R, et al. Safety and Outcome of Intravenous Thrombolysis in Stroke Patients on Prophylactic Doses of Low Molecular Weight Heparins at Stroke Onset. Stroke. 2019. PMID: 30943884. doi:10.1161/STROKEAHA.118.024575
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。